Search results for "IBD"

AMYLOIDOSIS AND INFLAMMATORY BOWEL DISEASE: FACT OR MITH?

2017

Inflammatory Bowel Disease (IBD), which includes both Crohn's Disease (CD) and Ulcerative Colitis (UC), is a chronic idiopathic inflammatory disorder affecting the gastrointestinal tract. Extraintestinal manifestations (EIM) are common in patients with IBD, and occur in 6-47% of patients with CD or UC. EIM can involve organs other than the gastrointestinal tract such as skin, eyes, joints, biliary tract and kidneis. Renal and urinary involvement particularly occurs in 4-23% of patients with IBD. Among the renal complications of IBD, seconfary amyloidosis (AA-type, AAA) is a rare but serious complication. renal amyloidosis has been proven to be the most common lethal manifestation of IBD-ass…

CROHN'S DISEASE AND EXTRAINTESTINAL GRANULOMATOUS LESIONS

2018

Crohn's disease (CD) is an inflammatory bowel disease with a multifactorial etiology. Clinical features include mucosal erosion, diarrhea, weight loss and other complications such as formation of granuloma. in CD, granuloma is a non-neoplastic epithelioid lesio, formed by a compact aggregate of histiocytes with the absence of a central necrosis, however, the correlation amomg CD and the formation of granulomas is unknown. Many casesof granulomas in the extracellular site, related to Cd, have been reported in the literature. These granulomas, at times, rapresented the only visible manifestation of the pathology. extra intestinal granuloma have been found on ovaries, lungs, male genitalia, fe…

Nutrition, malnutrition and dietary interventions in inflammatory bowel disease

2014

Inflammatory Bowel Disease (IBD), which includes both Crohn's disease (CD) and Ulcerative Colitis (UC), is a chronic idiopathic inflammatory disorder affecting the gastrointestinal tract. Diet, as a source of luminal antigens, is thought to be an important factor in the pathogenesis of IBD. often the nutritional status of patients is significantly compromised, particularly in CD. several factors, including drug-nutrient interactions, disease location, symptoms, and dietary restriction can lead to protein energy malnutrition and specific nutritional deficiencies. solid evidence regarding the accountability of certain dietary components in the etiology of IBD are lacking. With regard to malnu…

PROBIOTICI E TERAPIA CONVENZIONALE: NUOVE FRONTIERE NELLA GESTIONE DELLE MANIFESTAZIONI ARTICOLARI DELLE MALATTIE INFIAMMATORIE INTESTINALI (IBD)

2014

Summary: This work reports a clinical trial performed at palermo University Hospital "paolo Giaccone". From January 2004 to December 2011, 79 patients were enrolled (40 men and 39 women). All patients suffered from Inflammatory Bowel Disease (IBD) and were subjected to orthopedic consultation at the institute of Orthopaedics, University Hospital of palermo, for arthropathy to IBD. The patients were divided into two groups (A and B) and dealt with different therapies for the resolution of the inflammatory picture of the colonic mucosa and the treatment of the extraintestinal articular manifestations. Group A was treated with drug therapy: Diclofenac (75 mg im/ day for 10 days9 and Mesalazine…

INFLAMMATORY BOWEL DISEASE AND EXTRAINTESTINAL MANIFESTATIONS

2022

Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, are chronic and recurrent inflammatory diseases. Although the typical symptoms are localized in the gastrointestinal tract, there are also extraintestinal manifestations (EIMs) associated with IBD, probably caused by immune reactions secondary to the pathology of origin. Anybody can be affected by EIMs, which can be dermatological, pulmonary, ocular, musculoskeletal, hepatobiliary and neurological, et al. This represents a therapeutic challenge for clinicians, who must first establish a diagnostic and then a multidisciplinary therapeutic path, in order to guarantee an optimal quality of life for the patient.

Local Complications And Adverse Drug Reactions In Paediatric Inflammatory Bowel Disease

2014

Genotype / Phenotype analysis of a panel of genes in pediatric patients with IBD. A SIGENP multicentre study.

2006

ROLE OF NAKED CUTICLE HOMOLOG 1 GENE ON CHR 16Q12 IN INFLAMMATORY BOWEL DISEASE.

2010

INFLIXIMAB THERAPY IN MANAGING PEDIATRIC IBD

2012

Sicilian Network for Inflammatory Bowel Disease (SN-IBD). A propensity score-matched comparison of infliximab and adalimumab in naïve and non-naïve p…

2018

Background: In the absence of head-to-head trials, there is an unmeet need to better understand the relative effectiveness of different biologics in inflammatory bowel disease (IBD). The Sicilian Network for Inflammatory Bowel Disease (SN-IBD) is a group composed by all Sicilian centres which continuously enter in a web-based software all clinical data of IBD patients treated with biologics. Methods: Data of all incident Crohn’s disease (CD) patients treated with infliximab (IFX) and adalimumab (ADA) from January 2013 to April 2017 were extracted from the cohort of SN-IBD. Patients were divided in biologic-naïve and non-naïve, and the two groups were analysed singularly. We used a one-to-tw…